Kundar Rajeshwari, Gokarn Karuna
Department of Microbiology, Sir H.N. Medical Research Society, Sir H.N. Reliance Foundation Hospital & Research Centre, Mumbai 400004, Maharashtra, India.
Department of Microbiology, St. Xavier's College, 5- Mahapalika Marg, Mumbai 400001, Maharashtra, India.
Pharmaceuticals (Basel). 2022 Nov 30;15(12):1498. doi: 10.3390/ph15121498.
Rapidly emerging drug-resistant superbugs, especially Gram-negative bacteria, pose a serious threat to healthcare systems all over the globe. Newer strategies are being developed to detect and overcome the arsenal of weapons that these bacteria possess. The development of antibiotics is time-consuming and may not provide full proof of action on evolving drug-resistant pathogens. The clustered regularly interspaced short palindromic repeats/CRISPR-associated protein (CRISPR/Cas) systems are promising in curbing drug-resistant bacteria. This review focuses on the pathogenesis of Gram-negative bacteria, emergence of antimicrobial drug resistance, and their treatment failures. It also draws attention to the present status of the CRISPR-Cas system in diagnosisand treatment of Gram-negative bacterial infections.
迅速出现的耐药超级细菌，尤其是革兰氏阴性菌，对全球医疗系统构成了严重威胁。目前正在开发新的策略来检测并攻克这些细菌所拥有的一系列“武器”。抗生素的研发耗时长久，而且对于不断演变的耐药病原体可能无法提供十足有效的应对之策。成簇规律间隔短回文重复序列/CRISPR相关蛋白（CRISPR/Cas）系统在抑制耐药细菌方面颇具前景。本综述聚焦于革兰氏阴性菌的发病机制、抗菌药物耐药性的出现及其治疗失败情况。它还提请人们关注CRISPR-Cas系统在革兰氏阴性菌感染诊断和治疗方面的现状。
